Filing Flows › PAVmed (PAVM) › Q2 2026 › vs Q1 2026
PAVmed (PAVM) Q2 2026 vs Q1 2026 (quarter over quarter)
PAVmed's revenue rose $11K (+50%) from $22K in Q1 2026 to $33K in Q2 2026.
PAVmed, Q2 2026: revenue $33K (+450% year over year), net loss $6.6M, operating cash flow −$2.7M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $33K | $22K | $11K | +50% |
| Other income, net | $424K | $7.0M | −$6.5M | -94% |
| Net loss | $6.6M | $1.1M | $5.5M | +520% |
| Costs & expenses | $7.1M | $8.1M | −$1.0M | -12% |
| Operating costs | $7.1M | $8.1M | −$1.0M | -12% |
| Cost of revenue | $122K | $97K | $25K | +26% |
| Research & development | $2.1M | $1.4M | $679K | +49% |
| Sales & marketing | $215K | $216K | −$1K | -0.5% |
| General & admin | $4.7M | $6.4M | −$1.7M | -27% |
| Operating cash sources | $6.6M | $1.1M | $5.5M | +520% |
| Depreciation & amortization | $19K | $20K | −$1K | -5% |
| Share-based compensation | $917K | $182K | $735K | +404% |
| Working capital & other | $3.0M | −$1.8M | $4.8M | — |
| Cash used in operations | $2.7M | $2.6M | $43K | +2% |
| Net loss absorbed | $6.6M | $1.1M | $5.5M | +520% |
Questions
How much did PAVmed's revenue grow quarter over quarter in Q2 2026?
PAVmed's revenue rose $11K (+50%) from $22K in Q1 2026 to $33K in Q2 2026.